Kailera Therapeutics (Nasdaq: KLRA), a Waltham, Massachusetts-based clinical-stage biotechnology company focused on obesity treatment, priced its initial public offering at USD 16.00 per share on April 16, 2026, targeting gross proceeds of USD 625.0 million on the Nasdaq Global Select Market. If the IPO underwriters exercise their warrants, the listing will exceed USD 700 million in value. Kailera's listing is thought to represent a new record in terms of Nasdaq IPOs for biotechs, exceeding Moderna's previous benchmark of USD 604 million set in 2018.
The offering comprised 39,062,500 shares of common stock, all sold by the company. At the stated price, gross proceeds were USD 625.0 million before underwriting discounts, commissions, and offering expenses. Underwriters received a 30-day option to purchase up to an additional 5,859,375 shares at the IPO price less underwriting discounts and commissions. The offering was expected to close on April 20, 2026.
Kailera's lead asset is ribupatide (KAI-9531), a once-weekly injectable dual GLP-1/GIP receptor agonist being evaluated for obesity and chronic weight management. The company licensed ribupatide and three additional clinical-stage candidates from Jiangsu Hengrui Pharmaceuticals, retaining ex-China rights. Ribupatide is currently in the KaiNETIC global Phase III program, comprising three trials initiated between December 2025 and January 2026. The filing disclosed no FDA regulatory designations for any pipeline asset.
In a Hengrui-sponsored Phase II trial conducted in China, ribupatide at 8 mg once-weekly produced a mean body weight reduction of 23.6% from baseline at Week 36 versus 1.7–1.8% for placebo, with 59% of treated participants losing at least 20% of baseline body weight and no plateau observed at Week 36, the filing stated. A separate Hengrui-sponsored Phase III trial in China at 6 mg reported 19.2% mean body weight reduction at Week 48 with no plateau observed. KaiNETIC-1, the first of three global Phase III trials, enrolled adults with obesity or overweight without type 2 diabetes targeting approximately 1,800 participants, with topline results expected in 2028.